This is further supported by a recent study that showed correction of cardiac hypertrophy in the Mck conditional knockout mouse model by AAV-mediated FXN gene therapy, where frataxin was overexpressed tenfold over the level of endogenous frataxin expression without deleterious side effects in the treated mice.20 This evidence concerns the gene FXN and cardiac hypertrophy.